AWM
CLB icon

Abound Wealth Management’s Core Laboratories CLB Stock Holding History

Abound Wealth Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$129 – 1513
2025
Q4 		$129 Hold
8
– – ﹤0.01% 1333
2025
Q3 		$99 Hold
8
– – ﹤0.01% 1307
2025
Q2 		$93 Sell
8
-2
-20% -$24 ﹤0.01% 1265
2025
Q1 		$150 Hold
10
– – ﹤0.01% 1092
2024
Q4 		$174 Hold
10
– – ﹤0.01% 1127
2024
Q3 		$186 Buy
+10
New +$201 ﹤0.01% 1207

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abound Wealth Management's CLB Position: Q1 2026 in Review

Abound Wealth Management sold out of Core Laboratories (CLB) in Q1 2026, closing a stake of 8 shares — an estimated $129 sold.

Abound Wealth Management first reported a position in CLB in Q3 2024 and held it in 6 quarters. The position peaked at $186 in Q3 2024. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.

  • Abound Wealth Management reported no remaining Core Laboratories position as of Q1 2026 after selling out during the quarter.
  • Abound Wealth Management sold 8 Core Laboratories shares in Q1 2026, an estimated $129.
  • Abound Wealth Management first reported a position in Core Laboratories in Q3 2024 and held it in 6 quarters.
  • Abound Wealth Management's Core Laboratories position peaked at $186 in Q3 2024.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.

Based on Abound Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.